Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma

SIMPLE SUMMARY: The anti-tumor activity of anti-GD2 monoclonal antibodies (mAbs) have been demonstrated by the capacity to mediate immunological cytotoxicity but also through direct cell death induction. Recently, studies with anti-GD2 mAbs for high-risk (HR)-neuroblastoma (NB) patients with measura...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancers (Basel)
Glavni autori: Mora, Jaume, Castañeda, Alicia, Colombo, Maria Cecilia, Gorostegui, Maite, Gomez, Fernando, Mañe, Salvador, Santa-Maria, Vicente, Garraus, Moira, Macias, Napoleon, Perez-Jaume, Sara, Muñoz, Oscar, Muñoz, Juan Pablo, Barber, Ignasi, Suñol, Mariona
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7998131/
https://ncbi.nlm.nih.gov/pubmed/33809255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061264
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items